key: cord-0999153-a3p0xo26
authors: Hall, Victoria G.; Ferreira, Victor H.; Ierullo, Matthew; Ku, Terrance; Marinelli, Tina; Majchrzak‐Kita, Beata; Yousuf, Anila; Kulasingam, Vathany; Humar, Atul; Kumar, Deepali
title: Humoral and cellular immune response and safety of two‐dose SARS‐CoV‐2 mRNA‐1273 vaccine in solid organ transplant recipients
date: 2021-08-04
journal: Am J Transplant
DOI: 10.1111/ajt.16766
sha: 158c112a7567931cbe8f071d3642c2c4aada159d
doc_id: 999153
cord_uid: a3p0xo26

Solid organ transplant recipients are at high risk of severe disease from COVID‐19. We assessed the immunogenicity of mRNA‐1273 vaccine using a combination of antibody testing, surrogate neutralization assays, and T cell assays. Patients were immunized with two doses of vaccine and immunogenicity assessed after each dose using the above tests. CD4+ and CD8+ T cell responses were assessed in a subset using flow‐cytometry. A total of 127 patients were enrolled of which 110 provided serum at all time points. A positive anti‐RBD antibody was seen in 5.0% after one dose and 34.5% after two doses. Neutralizing antibody was present in 26.9%. Of note, 28.5% of patients with anti‐RBD did not have neutralizing antibody. T cell responses in a sub‐cohort of 48 patients showed a positive CD4+ T cell response in 47.9%. Of note, in this sub‐cohort, 46.2% of patients with a negative anti‐RBD, still had a positive CD4+ T cell response. The vaccine was safe and well‐tolerated. In summary, immunogenicity of mRNA‐1273 COVID‐19 vaccine was modest, but a subset of patients still develop neutralizing antibody and CD4+T‐ cell responses. Importantly polyfunctional CD4+T cell responses were observed in a significant portion who were antibody negative, further highlighting the importance of vaccination in this patient population. IRB Statement: This study was approved by the University Health Network Research Ethics Board (CAPCR ID 20–6069).

Solid organ transplant (SOT) recipients are at high risk for complications from infection with the coronavirus disease 2019 . 1, 2 The use of exogenous immunosuppression in these patients hampers the response to most viral infections as well as diminishing the utility of preventative and therapeutic measures.

Transplant patients may also have prolonged viral shedding potentially leading to increased infectivity and variant development. 3 Public health strategies including the use of masks, physical distancing, testing of symptomatic individuals, contact tracing, and isolation have had variable success in preventing infections. In this context, multiple vaccine platforms have been investigated to try to impede the spread of COVID-19. [4] [5] [6] While vaccines have proven extremely successful in the general population much less is known in immunocompromised patients.

The mRNA-1273 vaccine (Moderna), a lipid nanoparticleencapsulated mRNA-based vaccine encoding the perfusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was found to be highly effective and safe in a phase III, randomized, placebo-controlled trial involving 30,420 immunocompetent volunteers. 4 Similar results have been reported for another mRNA vaccine, BNT162b2 (Pfizer-BioNTech). 5 However, in immunocompromised populations, including SOT recipients, humoral vaccine immune response appears to be diminished or even absent in some individuals. 7 Poor response to the vaccine has been associated with the use of anti-metabolite immunosuppression as well as other transplant-specific risk-factors. 7, 8 Currently published studies in transplant recipients have used different assays to measure humoral responses, but measurement of antibody against the receptor binding domain of the SARS-CoV-2 spike protein (anti-RBD) seems to be a relevant end-point. However, the neutralizing capacity of the antibody response is also important in that this measures the ability of detectable antibodies to block infection. Neutralizing antibody levels have recently been convincingly shown to be highly predictive of immune protection from symptomatic SARS-CoV-2 infection across multiple large studies. 9 Another important aspect of the vaccine response is cellular immunity and specifically the CD4+ T cell response. 10 There are limited data on both neutralizing antibody and T cell responses post-vaccine in SOT recipients. In this study, we performed a comprehensive assessment of antibody and cell-mediated immune responses to two doses of SARS-CoV-2 mRNA-1273 (Moderna) in SOT recipients.

This was a prospective observational cohort study of SOT recipients recruited from a tertiary care transplant program, who were receiving the two scheduled doses of the mRNA-1273 vaccine (Moderna) 28 days apart. We enrolled adult patients (aged ≥18 years) who had received an organ transplant (kidney, liver, heart, lung and pancreas, or combined organs), had a functioning allograft, and were planning to receive the mRNA-1273 vaccine series. Those who completed the two-dose SARS-CoV-2 mRNA-1273 vaccine series between March 2, 2021-April 8, 2021 were included and followed to 6 weeks after the second dose. Exclusion criteria were as follows: less than 6-months post-transplant, previous confirmed COVID-19 infection, experienced a febrile illness within 1-week prior to vaccination, active cytomegalovirus infection (defined as viral load of >1000 IU/mI or a lower viral load accompanied by compatible symptoms), receipt of intravenous immunoglobulin in the past 30 days or planning to receive intravenous immunoglobulin in the next 4 weeks. The local institutional research ethics board approved the study and all patients provided written informed consent. A subset of patients also provided consent for additional blood for T cell immunity studies.

Blood samples were obtained before dose one (V0), 4 weeks after the first dose (V1) and within 4-6 weeks after the second dose of vaccine (V2) for testing. A group of transplant patients with natural COVID-19 infection who had given informed consent to provide convalescent serum was also used for a comparator.

The primary outcome was a measure of IgG antibody against the receptor binding domain of the spike protein (anti-RBD). This was measured by semi-quantitative anti-spike serologic testing using the Roche Elecsys anti-SARS-CoV-2 S enzyme immunoassay. 11 Testing was performed as per manufacturer's instructions in a certified biochemistry testing laboratory. This assay has a lower limit of detection (LOD) of 0.4 U/ml and as per test instructions, a positive response is defined as ≥0.8 U/ml. Neutralizing antibodies were assessed via the SARS-CoV-2 Surrogate Virus Neutralization Test (SVNT) assay (GenScript), according to the manufacturer's specifications. This SVNT assay has received emergency use authorization from the FDA. This assay works by incubating serum with horseradish peroxidase (HRP)-conjugated spike-RBD and then transferring the mixture to ACE2 coated wells. If neutralizing antibodies are present in the serum, the RBD-ACE2 interactions are blocked. The SVNT measures total neutralizing antibodies in sera. The assay was originally described by Tan et al. 12 and has been used in several peer-reviewed studies to assess neutralizing antibodies outside of biosafety level 3 (BSL3) facilities. [13] [14] [15] According to the manufacturer's instructions, a positive is defined based on a neutralizing antibody threshold of 30% neutralization/inhibition or greater. At this cut-off, the negative and positive percent agreement with conventional plaque reduction neutralization test (PRNT) 50 and PRNT 90 assays is approximately 100%. The manufacturer reported sensitivity and specificity for the assay is 93.80% and 99.4% respectively. As per kit specifications, patients with neutralization below 30% were considered negative for neutralizing antibodies.

In a subset of consenting participants, SARS-CoV-2 specific CD4+ and CD8+ T cell responses were assessed. Peripheral blood mononuclear cells (PBMCs) were isolated, and cryopreserved in liquid nitrogen using a validated protocol to ensure high cell viability. A total of 10 6 PBMCs were rested for 2 h and incubated with overlapping peptides encompassing the full SARS-CoV-2 spike protein.

Peptides consisted mainly of 15-mer sequences with 11 amino acid overlaps (PepTivator ® , Miltenyi Biotec) and were included at a final concentration of 5 µg/mI per peptide, based on preliminary studies to determine optimal concentration. Cells were incubated overnight with peptides, a CD28/CD49d co-stimulatory antibody cocktail (BD Biosciences) and a protein transport inhibitor to prevent cytokine release (ThermoFisher Scientific). Intracellular cytokine staining (ICS) was used to measure the frequency of spike-specific T cells, as has been commonly done in other SARS-CoV-2 vaccine studies. [16] [17] [18] [19] The cytokine effectors used in this study were the principle Th1 effectors, IFNγ and IL-2, which have been used to evaluate SARS-CoV-2reactive T cells following immunization with mRNA-1273. 10,20 PMA/ ionomycin was used as a positive control and cells treated with media alone were used as a negative (media) control. Following incubation at 37°C, cells were stained with a viability dye (Zombie Aqua, Biolegend), Fc blocked (BD Biosciences) and incubated with a surface marker antibody cocktail (CD3, CD4, CD8). Cells were then fixed, permeabilized, and incubated with an antibody cocktail to detect intracellular markers (IFNγ and IL-2). Table S1 lists the antibodies used in this study, their clones, suppliers, and associated fluorochromes.

Flow cytometry was performed on an LSR II BGRV (BD Biosciences) at the SickKids-UHN Flow Cytometry Facility. A representative gating strategy is shown in Figure SA . As a robust, validated, yet conservative measure of vaccine-induced T cell responses, we specifically measured frequencies of CD4+ and CD8+ T cells that expressed two cytokines (IFNγ and IL-2 positive). Polyfunctional T cells are commonly used to assess vaccine-induced immunogenicity. [16] [17] [18] The frequency of vaccine-antigen specific T cells was determined by subtracting the frequency of polyfunctional T cells in untreated comparators from the frequency in peptide-stimulated samples. A positive T cell response was defined as minimum of 3-standard deviations above the mean of the background, plus a minimal polyfunctional T cell frequency of 0.01%, which was set as the limit of quantitation (LOQ). A minimum number of 100,000 live, CD3+ T cells were required for samples to be included in the flow analysis. These conditions and definitions were validated using samples from healthy controls (vaccinated and post-recovery from COVID-19), and represent a conservative measure of a positive T cell response to ensure robustness of the reported data.

All patients were followed closely for the duration of the study. Safety assessments included monitoring through a participant-directed vaccine diary for local and systemic adverse events for 7 days after each injection. Adverse events were categorized by the Food and Drug Administration toxicity grading scale for volunteers in vaccine trials as follows; grade 1 (no interference in daily activities), grade 2 (some interference in daily activities), grade 3 (participants unable to perform daily activities), and grade 4 (potentially life threatening). 19 In addition, study team members contacted all participants every 2 weeks by phone call and chart review for episodes of acute organ rejection, hospitalization, other adverse events, or COVID-19 infection for ≥60 days post first dose of vaccine or until May 21, 2021.

The immunogenicity analysis was performed in those who received 

The primary outcome was incidence of positive serologic response based on measurement of anti-RBD antibody. Normalized anti-RBD levels pre-vaccine, after the first dose, and after the second dose are shown in Figure 2 . After dose one, the response rate was 6/121 

The presence of neutralizing antibody using the validated surrogate virus neutralization test (SVNT) was determined for all vaccine patients. The neutralizing antibody results are shown in Figure 3 and Figure SD . We found that after the first dose 7/119 (5.9%) had 

A summary of SARS-CoV-2 specific CD4+ and CD8+ T cell responses are shown in Figure 4 . Representative cytokine plots for a "higher"

and "lower" responding patient are shown in Figure 

Safety analysis was completed for all participants out to the end of the study period for 108/127 (85%) patients who completed the in the same frequency range as has been reported in healthy volunteers. 18, 23 It was also encouraging that many patients had evidence of neutralizing antibody. Neutralization levels have recently been robustly shown to be highly predictive of immune protection in immunocompetent cohorts. 9 Of note, though, is that approximately 28.5%

of patients in our study with a positive anti-RBD response did not have neutralizing antibody. These patients typically had very low levels of anti-RBD detected (median 1.83 U/ml, range 1.19-20.9 U/mI).

In a study of 80 liver transplant recipients, vaccinated with Pfizer-BioNTech COVID vaccine, the response rate was 47.5% using an S1/S2 chemiluminescent assay. Age, triple immunosuppression, and mycophenolate use were associated with poor response. 24 IgG against S1. 7 The response rate after two doses was 54%. 7 Again use of antimetabolite immunosuppression was associated with poor In summary, we assessed Moderna vaccine responses in a cohort of solid organ transplant recipients. We show that the vaccine response rate by anti-RBD was 34.5% and 26.9% had evidence of neutralizing antibodies. However, we also show that a significant number of patients had a positive SARS-CoV-2 specific CD4+ T cell response often in the absence of a detectable antibody response.

The latter highlights the importance of vaccinating all transplant recipients and not assuming poor immunogenicity based on antibody response alone. Despite vaccination or antibody status, we encourage ongoing vigilance from SOT recipients, who are still at risk for breakthrough COVID-19 infection, in particular in the context of the circulating variants of concern including Alpha and Delta variants.

Our data also suggest that it is likely these patients could still benefit from further strategies to enhance immunogenicity; such as booster 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Victoria G. Hall https://orcid.org/0000-0001-9353-0059

Terrance Ku https://orcid.org/0000-0002-6757-3757

Deepali Kumar https://orcid.org/0000-0003-1961-0477

COVID-19 in solid organ transplant: a multi-center cohort study

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

An mRNA vaccine against SARS-CoV-2 -preliminary report

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

A new SARS-CoV-2 dualpurpose serology test: highly accurate infection tracing and neutralizing antibody response detection

Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients

T-cell responses following natural influenza infection or vaccination in solid organ transplant recipients

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Guidance for Industry -Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Food and Drug Administration

Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients

Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine

Safety and immunogenicity of two RNA-based covid-19 vaccine candidates

Substantial differences in SARS-CoV-2 antibody responses elicited by natural infection and mRNA vaccination

Durability of responses after SARS-CoV-2 mRNA-1273 VACCINATION

Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients